ClinicalTrials.gg
TerminatedNCT03678506APIDULCISUpdated Feb 24, 2023

Apixaban for Extended Anticoagulation (APIDULCIS)

A Phase 4 interventional study of Apixaban in Venous Thromboembolism and Anticoagulants, sponsored by Arianna Anticoagulazione Foundation. Terminated at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Arianna Anticoagulazione Foundation · Phase 4, Interventional, and Prevention

How we know

Why this study was terminated
The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval \[CI\], 4.5-11.2)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.

Enrollment
9th of 37
800 · median 100
Started
2018
with 2 others
Phase 4
14 of 37
5 open now
Registered
19th of 37
by date
Lead sponsor
1 of 37
Arianna Anticoagulazione Foundation

Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 9th largest by enrollment, is one of 3 that started in 2018, is one of 14 in phase 4, and was the 19th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing apixaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

Read the detailed description

This prospective cohort study aims to assess the efficacy and safety of a management procedure to decide on giving or not an extended anticoagulation (administering apixaban 2 2.5 mg twice daily ) to outpatients with a single episode of proximal deep vein thrombosis of the lower limbs and/or pulmonary embolism who had received 12-15 months of anticoagulation (whatever the anticoagulant drug used). The study seeks to assess whether a management procedure involving D-dimer testing assessment can identify a subset of subjects at low risk of recurrence in whom an extended anticoagulation can be safely avoided.

03

Conditions studied

  • Venous Thromboembolism
  • Anticoagulants

Keywords

  • Venous thromboembolism
  • D-Dimer
  • Apixaban
  • Extended treatment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First unprovoked Venous Thromboembolic Event
  • Venous Thromboembolic events associated with one or more risk factors that are no longer present
  • Age older than 18 or younger than 75 years
  • Capacity to give written

Exclusion criteria

Exclusion Criteria:

  • A) Exclusion criteria regarding the index event
  • Events usually associated with low risk of recurrence
  • Deep vein thrombosis/ Pulmonary embolism occurred within 3 months from major surgery or major trauma
  • Isolated Distal deep vein thrombosis (thrombosis of calf veins)
  • Events associated with a very high risk of recurrence or occurrence of life-threatening recurrent events

    • Pulmonary Embolism episode with shock or life-threatening
    • Isolated pulmonary embolism with a systolic pulmonary artery pressure > 60 mmHg at presentation
    • Deep vein thrombosis/ Pulmonary embolism associated with active cancer, antiphospholipid syndrome or long-standing medical illnesses
    • More than one idiopathic event
  • Index venous thromboembolic event in different sites than deep veins of the lower limbs or pulmonary arteries

B) Exclusion criteria present at the moment of patients' screening:

  • Age younger than 18 or older than 75 years
  • More documented unprovoked venous thromboembolic episodes
  • Pregnancy or puerperium
  • Severe post-thrombotic syndrome (≥ 15 points at the Villalta score)
  • Solid neoplasia or blood disease in active phase or requiring chemotherapy/radiotherapy
  • All the clinical conditions requiring prolonged treatment with Low Molecular Weight Heparin
  • Presence of overt, active chronic diseases (i.e. inflammatory bowel disease)
  • Known serious thrombophilic alterations:

    • deficiencies of natural anticoagulants (Antithrombin, Protein C, Protein S)
    • homozygosity for Factor V Leiden or Factor II G20210A mutations
    • double heterozygosity
  • Presence of antiphospholipid syndrome
  • Presence of vein cava filter
  • Concomitant conditions (such as atrial fibrillation) requiring indefinite anticoagulation
  • Severe cardio-respiratory insufficiency ( 3 or 4)
  • Any absolute to anticoagulation treatment
  • Any other contraindications to Apixaban as per local SmPC
  • shorter than 1 year
  • Refuse interruption of anticoagulation to perform serial D-dimer assessment
  • Geographically inaccessible location
  • Inability or refusal to give consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (actual)

Study arms

  • Experimental
    Positive D-Dimer

    At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.

    Drug: Apixaban

  • No intervention
    Negative D-Dimer

    Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.

Interventions

  • Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results

    Also known as: Apixaban and positive d-dimer

06

What researchers measure

Primary outcomes

  1. Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).

    The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 18 months

  2. Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)

    Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to18 months

Secondary outcomes

  1. Number of and rate of thromboembolic events

    Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 18 months

  2. Presence of severe post-thrombotic syndrome according to Villalta Score

    Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score \> of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome

    Time frame: 18 months

  3. Number and rate of non major bleeding complications

    In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation

    Time frame: From date of enrollment until the date of first documented event assessed up to18 months

  4. Number and rate of dead patients (overall mortality)

    VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 18 months

07

Study locations

1 site
  • Daniela Poli
    Firenze, 50134, Italy
08

References and documents

Publications

  • Palareti G, Poli D, Ageno W, Legnani C, Antonucci E, Bucherini E, Testa S, Paoletti O, Chistolini A, Serrao A, Martinelli I, Bucciarelli P, Falanga A, Tosetto A, Sarti L, Mastroiacovo D, Cosmi B, Visona A, Santoro RC, Zanatta N, Grandone E, Bertu L, Pengo V, Caiano L, Prandoni P. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. Blood Adv. 2022 Dec 13;6(23):6005-6015. doi: 10.1182/bloodadvances.2022007973. PubMed 35914222 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All collected data will be shared

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The data will be available after the publication of global results of the study or after 18 months from the enrollment of the last patients

Access criteria: Data access requests will be reviewed by the Scientific board of the study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Sep 2021, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2018
First posted
Sep 19, 2018
StartActual
Aug 16, 2018
Primary completionActual
Sep 1, 2021
CompletionActual
Jan 31, 2023
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03678506
Lead sponsor
Arianna Anticoagulazione Foundation
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Aug 16, 2018
Primary completion
Sep 1, 2021
Completion
Jan 31, 2023
Last update
Feb 24, 2023

Study contacts

Daniela Poli, MD
study director · Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion